Nanobiotix S.A. (NBTX), announced that, following a temporary halt earlier in that day, trading of its ordinary shares on Euronext Paris resumed at 3:30 p.m. Paris time (9:30 a.m. New York time) on May 21, 2026.
Context of the Resumption
Trading has been temporarily halted earlier that day at the company's request to allow for investor allocation confirmation and pricing of its previously announced global offering, which includes a U.S. public offering of American Depositary Shares (ADSs) and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the U.S and Canada.
Company Background
Founded in 2003 and headquartered in Paris, Nanobiotix has been listed on Euronext since 2012 and on the Nasdaq Global Select Market since 2020. The company owns more than 25 patent families across three nanotechnology platform with applications in oncology, bioavailability and biodistribution, and central nervous system disorders.
NBTX has traded between $3.66 and $57.14 over the past year. The stock is currently trading at $41.79, down 3.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.